Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816

Biochemical and Biophysical Research Communications

Volumn 410, Issue 2, 2011, Pages 224-228

  Kim, Soo Young ^b   Kang, Jamie J ^b,c   Lee, Hyung Hoan ^b,d   Kang, Jenny J ^b,e   Kim, BoKyung ^a   Kim, Chan Gil ^a   Park, Tae Kyu ^a   Kang, Hyun ^a  

^a Konkuk University   (South Korea)

^b Konkuk University   (South Korea)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d Dongbang Culture Graduate University   (South Korea)

^e YALE UNIVERSITY   (United States)

Author keywords

C KIT; Dimers; Phosphorylation; SCF

Indexed keywords

ASPARTIC ACID; DIMER; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DNA STRUCTURE; ENZYME ACTIVATION; GASTROINTESTINAL STROMAL TUMOR; HEMATOPOIETIC CELL; HUMAN; INTERNAL TANDEM DUPLICATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; WILD TYPE;

AMINO ACID SEQUENCE; ASPARTIC ACID; CELL MEMBRANE; ENZYME ACTIVATION; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; POINT MUTATION; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; TYROSINE;

EID: 79959763366     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.111     Document Type: Article

References (28)

1. Broudy V. Stem cell factor and hematopoiesis. Blood 1997, 90:1345-1364.
2. Glocker M.O., Arbogast B., Schreurs J., Deinzer M.L. Assignment of the inter- and intra-molecular disulfide linkages in recombinant human macrophage colony stimulating factor using fast atom bombardment mass spectrometry. Biochemistry 1993, 32(2):482-488.
3. Rosnet O., Buhring H.J., Marchetto S., Rappold I., Lavagna C., Sainty D., et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996, 10(2):238-248.
4. Ulich T.R., del Castillo J., Watson L.R., Yin S.M., Garnick M.B. In vivo hematologic effects of recombinant human macrophage colony-stimulating factor. Blood 1990, 75(4):846-850.
5. Beghini A., Ripamonti C.B., Cairoli R., Cazzaniga G., Colapietro P., Elice F., et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia and identification of an internal tandem duplication. Haematologica 2004, 89(8):920-925.
6. Wang Y.Y., Zhou G.B., Yin T., Chen B., Shi J.Y., Liang W.X., et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc. Natl. Acad. Sci. USA 2005, 102(4):1104-1109.
7. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112(4):946-956.
8. Pignon J.M., Giraudier S., Duquesnoy P., Jouault H., Imbert M., Vainchenker W., et al. A new c-kit mutation in a case of aggressive mast cell disease. Br. J. Haematol. 1997, 96(2):374-376.
9. Duensing A., Heinrich M.C., Fletcher C.D., Fletcher J.A. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest. 2004, 22(1):106-116.
10. Ali S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 2007, 401(1-2):38-45.
11. Ning Z.Q., Li J., McGuinness M., Arceci R.J. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity. Oncogene 2001, 20(33):4528-4536.
12. Ning Z.Q., Li J., Arceci R.J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 2001, 97(11):3559-3567.
13. Antonescu C.R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 2005, 11(11):4182-4190.
14. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003, 21(23):4342-4349.
15. Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y., Sang B.C., et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 2003, 278(34):31461-31464.
16. Growney J.D., Clark J.J., Adelsperger J., Stone R., Fabbro D., Griffin J.D., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005, 106(2):721-724.
17. Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I., Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007, 130(2):323-334.
18. Liu H., Chen X., Focia P.J., He X. Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J. 2007, 26(3):891-901.
19. Roskoski R. Signaling by Kit protein-tyrosine kinase - The stem cell factor receptor. Biochem. Biophys. Res. Commun. 2005, 337(1):1-13.
20. Masson K., Heiss E., Band H., Ronnstrand L. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination internalization and degradation. Biochem. J. 2006, 399(1):59-67.
21. Samayawardhena L.A., Hu J., Stein P.L., Craig A.W. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor. Cell. Signal. 2006, 18(9):1447-1454.
22. Taylor M.L., Metcalfe D.D. Kit signal transduction. Hematol. Oncol. Clin. North Am. 2000, 14(3):517-535.
23. Kitayama H., Kanakura Y., Furitsu T., Tsujimura T., Oritani K., Ikeda H., et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995, 85(3):790-798.
24. Paulhe F., Wehrle-Haller M., Jacquier M.C., Imhof B.A., Tabone-Eglinger S., Wehrle-Haller B. Dimerization of Kit-ligand and efficient cell-surface presentation requires a conserved Ser-Gly-Gly-Tyr motif in its transmembrane domain. FASEB J. 2009, 23(9):3037-3048.
25. Broudy V.C., Lin N.L., Buhring H.J., Komatsu N., Kavanagh Y.J. Analysis of c-kit receptor dimerization by fluorescence resonance energy transfer. Blood 1998, 91(3):898-906.
26. Jahn .T., Seipel P., Coutinho S., Urschel S., Schwarz K., Miething C., et al. Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain. Oncogene 2002, 21(29):4508-4520.
27. Kang H., Freund C., Duke-Cohan J.S., Musacchio A., Wagner G., Rudd C.E. SH3 domain recognition of a proline-independent tyrosine-based RKxxYxxY motif in immune cell adaptor SKAP55. EMBO J. 2000, 19(12):2889-2899.
28. Corbacioglu S., Kilic M., Westhof M.A., Reinhardt D., Fulda S., Debatin K.M. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006, 108(10):3504-3513.